Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40 years for asthma is used

Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Hannu Kankaanranta
European Respiratory Journal 2017 50: 1700871; DOI: 10.1183/13993003.00871-2017
Minna Tommola
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: minna.tommola@epshp.fi
Pinja Ilmarinen
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leena E. Tuomisto
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannu Kankaanranta
1Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland
2University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The suggested asthma-onset age limit of 40 as a criterion for ACOS may lead to severe underdiagnosis of ACOS http://ow.ly/rVSk30ckrOq

To the Editor:

In a recent issue of the European Respiratory Journal, Sin et al. [1] presented recommendations on the definition of asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS). The presented conclusions, based on a round table discussion, are very important and notable, especially considering the current lack of specific clinical criteria for ACOS. One of the key recommendations is that asthma or atopy should be diagnosed before age of 40 years (or patients should have very large airway reversibility) in order to fulfil the criteria of ACOS. However, the scientific basis of using the 40-year cut-off remains debatable. In addition, the proposal raises a major concern of underdiagnosing adult-onset asthma and ACOS if the suggested age limit is used.

ACOS has been described to develop mainly by two pathways: 1) patients with previous COPD develop asthma-like symptoms and/or asthmatic characteristics (e.g. large reversibility of the airways); or 2) patients with previous asthma continue smoking and develop nonreversible bronchial obstruction, which indicates COPD [2, 3]. The prevalence of ACOS is suggested to be 12–55% among patients with COPD and 13–61% among patients with asthma [2]. These numbers reflect the relatively large impact of ACOS and necessitate diagnostic accuracy.

Based on cluster analyses, different phenotypes have been recognised in asthma and the age of onset has been found to be a key factor distinguishing these phenotypes [4, 5]. Early-onset asthma has typically been associated with atopy and allergies, and characterised by a good response to inhaled corticosteroids and relatively high remission rate [4, 5]. Adult-onset asthma, on the other hand, has received less attention. Recent studies have suggested adult-onset asthma to have lower remission rates [5, 6], more rapid loss of lung function [5] and poorer prognosis [6, 7]. In a recent study of age-specific incidence of new asthma diagnoses in Finland, it was reported that most diagnoses of persistent asthma are actually made in adulthood [8]. In a US-based study, the adult-onset phenotype was reported to dominate especially among women [9]. Moreover, in a clinical cohort of consecutive, new adult-onset asthma patients (Seinäjoki Adult Asthma Study [6, 10]), the mean±sd age of asthma onset was found to be 46±13.7 years, which is substantially higher than the suggested limit [6, 10]. These findings raise a question of whether the age limit of 40 years is actually applicable to real-life clinical work.

In Finland, every patient with persistent asthma is entitled to asthma reimbursement by the Social Insurance Institution of Finland (SII). The number of new asthma reimbursements reflects the number of novel asthma diagnoses made. We obtained numbers of patients from the SII and evaluated the age at which the reimbursement was obtained in Finland during 2012–2013, in order to evaluate whether diagnoses of persistent asthma were made either before or after 40 years of age. Data acquisition and calculation of novel asthma medication reimbursements were made as previously described [8].

In 2012–2013, in Finland (population 5.4 million), 26 281 new patients were entitled to special reimbursement for their asthma medication (13 941 females and 12 340 males). Of these, only 12 095 (46.0%) persons belonged to age group 0–39 years, indicating that a majority (54.0%) of new patients who obtained special asthma medication reimbursement were older than 40 years (figure 1). More than half (57.9%) of females were ≥40 years; in contrast, 50.5% of men obtained asthma reimbursement before their 40th birthday (figure 1). In conclusion, these results further suggest that most asthma is diagnosed after 40 years of age, and thus emphasise the impact and importance of adult-onset asthma. The criterion for asthma reimbursement in Finland is variable airway obstruction demonstrated by objective lung function measurements [8]; thus, misclassified COPD does not explain the result, even though this analysis contains patients with a history of smoking.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Proportion of novel asthma reimbursements in age groups 0–39 and ≥40 years.

The perception of asthma being merely a childhood-onset disease persists; however, the adult-onset phenotype of asthma has been identified in several studies and is recognised by guidelines. There is already evidence that a majority of persistent asthma may actually start in adulthood [8, 9], making it necessary to take patients with adult-onset asthma into consideration when the starting age of asthma is recommended as a diagnostic criterion. In order to obtain a diagnosis, and administer good and increasingly personalised therapy to our ACOS patients, the diagnostics must be accurate and sensitive regardless of sex, age and smoking status. Using the suggested age limit of 40 years as a criterion for ACOS may lead to severe underdiagnosis of ACOS when patients with asthma onset after 40 years of age are not included. This especially concerns women. Thus, we propose that the suggested age limit of asthma onset in the criteria of ACOS should be reconsidered.

Disclosures

Supplementary Material

P. Ilmarinen ERJ-00871-2017_Ilmarinen

H. Kankaanranta ERJ-00871-2017_Kankaanranta

M. Tommola ERJ-00871-2017_Tommola

L.E. Tuomisto ERJ-00871-2017_Tuomisto

Acknowledgements

We thank senior statistical analyser Timo Partio from the Social Insurance Institution of Finland for providing the data.

Footnotes

  • Support statement: This work was supported by the Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), Tampere Tuberculosis Foundation (Tampere, Finland), Research Foundation of the Pulmonary Diseases (Helsinki), Jalmari and Rauha Ahokas Foundation (Helsinki), Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere), and Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received April 27, 2017.
  • Accepted April 27, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Sin DD,
    2. Miravitlles M,
    3. Mannino DM, et al.
    What is asthma–COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016; 48: 664–673.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wurst KE,
    2. Kelly-Reif K,
    3. Bushnell GA, et al.
    Understanding asthma–chronic obstructive pulmonary disease overlap syndrome. Respir Med 2016; 110: 1–11.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Barrecheguren M,
    2. Esquinas C,
    3. Miravitlles M
    . The asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015; 21: 74–79.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wenzel SE
    . Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
    OpenUrlCrossRefPubMed
  5. ↵
    1. de Nijs SB,
    2. Venekamp LN,
    3. Bel EH
    . Adult-onset asthma: is it really different? Eur Respir Rev 2013; 22: 44–52.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Tuomisto LE,
    2. Ilmarinen P,
    3. Niemelä O, et al.
    A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. Respir Med 2016; 117: 223–229.
    OpenUrl
  7. ↵
    1. Tuomisto LE,
    2. Ilmarinen P,
    3. Kankaanranta H
    . Prognosis of new-onset asthma diagnosed at adult age. Respir Med 2015; 109: 944–954.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kankaanranta H,
    2. Tuomisto LE,
    3. Ilmarinen P
    . Age-specific incidence of new asthma diagnoses in Finland. J Allergy Clin Immunol Pract 2017; 5: 189–191.
    OpenUrl
  9. ↵
    1. Sood A,
    2. Qualls C,
    3. Schuyler M, et al.
    Adult-onset asthma becomes the dominant phenotype among women by age 40 years. Ann Am Thorac Soc 2013; 10: 188–197.
    OpenUrl
  10. ↵
    1. Tommola M,
    2. Ilmarinen P,
    3. Tuomisto LE, et al.
    The effect of smoking on lung function: a clinical study of adult-onset asthma. Eur Respir J 2016; 48: 1298–1306.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 2 Table of Contents
European Respiratory Journal: 50 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40 years for asthma is used
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40 years for asthma is used
Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Hannu Kankaanranta
European Respiratory Journal Aug 2017, 50 (2) 1700871; DOI: 10.1183/13993003.00871-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40 years for asthma is used
Minna Tommola, Pinja Ilmarinen, Leena E. Tuomisto, Hannu Kankaanranta
European Respiratory Journal Aug 2017, 50 (2) 1700871; DOI: 10.1183/13993003.00871-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Ivacaftor modifies cystic fibrosis neutrophil phenotype
  • Serum mitochondrial DNA predicts exacerbation and progression of IPF
  • CTEPH and totally implantable central venous access systems
Show more Agora

Correspondence

  • Non-animal models for COVID-19 lung research
  • User-life of ICS/LABA inhaler devices should be considered
  • Peripheral blood eosinophil counts in European and East Asian populations
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society